Effectiveness of ChatGPT and DeepSeek in Urology Medical Education: Randomized Controlled Trial.

J Med Internet ResSep 21, 2026 (epub)
Clinical ResearchUrology

Wentong Yang, Ting Xu, Junjie Wei et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the effectiveness of generative AI tools, ChatGPT o3-mini and DeepSeek R1, in urology education among medical undergraduates. DeepSeek R1 outperformed ChatGPT in accuracy and posttest scores, indicating its potential as a superior educational tool. The study highlights the feasibility of integrating AI into medical curricula.

Key findings

  • DeepSeek R1 had higher accuracy than ChatGPT o3-mini in answering urology multiple-choice questions.
  • Students using DeepSeek R1 achieved higher total scores than both the control and ChatGPT groups.
  • Most students expressed a positive attitude towards AI-assisted learning in medical education.

Why it matters

The integration of AI tools like DeepSeek R1 in medical education could enhance learning outcomes, providing educators with innovative methods to improve teaching strategies and student engagement in complex subjects like urology.

Source

PubMed · PMID 42766393

Published in J Med Internet Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Urology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.